Lipids and Transaminase in Antiretroviral-Treatment-Experienced People Living with HIV, Switching to a Doravirine-Based vs. a Rilpivirine-Based Regimen: Data from a Real-Life SettingPaolo Maggi, Paolo Bonfanti, Barbara Menzaghi et al.|Viruses|2023Cited by 17
Risk of Cardiovascular Events in People with HIV (PWH) Treated with Integrase Strand-Transfer Inhibitors: The Debate Is Not Over; Results of the SCOLTA StudyPaolo Bonfanti, Barbara Menzaghi, Giancarlo Orofino et al.|Viruses|2024Cited by 13
Abstract Supplement HIV Glasgow 10–13 November 2024, Glasgow, UK/VirtualL Taramasso, Paolo Bonfanti, Nicola Squillace et al.|Journal of the International AIDS Society|2024Cited by 13
SC28 Adverse event development in people with HIV on long-acting Cabotegravir + rilpivirine: timing and clinical insightsGaia Cologgi, Antonio Di Biagio, L Taramasso et al.|Unknown|2025Cited by 0
Lipids and Body Mass Index in Antiretroviral‐Experienced People With HIV on Doravirine‐Based Treatments: A Comparison Between Dual or Triple Regimen Versus Bictegravir‐Based Triple RegimenPaolo Maggi, Addolorata Masiello, Barbara Menzaghi et al.|AIDS Research and Treatment|2025Cited by 0